Quarterly ResultAug 12, 2026, 04:25 PM
MIRA PHARMACEUTICALS Reports Q2 Net Loss of $1.2M; Going Concern Doubt
AI Summary
MIRA Pharmaceuticals reported a net loss of $1.2 million for the three months ended June 30, 2026, and $2.4 million for the six months, an improvement compared to the prior year. However, the company faces significant liquidity challenges, with cash decreasing to $3.6 million and a "going concern" warning due to insufficient funds for the next 12 months. Research and development expenses increased to $1.2 million for the six-month period, while general and administrative expenses decreased. The company continues to advance its clinical pipeline, including Ketamir-2, MIRA-55, and SKNY-1, and holds an equity investment in Telomir Pharmaceuticals.
Key Highlights
- Net loss for Q2 2026 was $1.2 million, an improvement from $1.5 million in Q2 2025.
- Cash balance decreased to $3.6 million as of June 30, 2026, from $6.3 million at December 31, 2025.
- Company issued a "going concern" warning due to insufficient cash for the next 12 months.
- Research and development expenses increased to $1.2 million for the six months ended June 30, 2026.
- General and administrative expenses decreased to $1.0 million for the six months ended June 30, 2026.
- Issued 83,500 fully vested restricted stock units to its CEO, recognizing $86,005 compensation expense.
- Expanded license agreements for Ketamir-2, SKNY-1, and MIRA-55 with related party MIRALOGX.
Price Impact
More from MIRA